| 5.12 0.87 (20.47%) | 03-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.34 | 1-year : | 10.46 |
| Resists | First : | 7.14 | Second : | 8.96 |
| Pivot price | 6.33  |
|||
| Supports | First : | 4.19 | Second : | 3.49 |
| MAs | MA(5) : | 5 |
MA(20) : | 6.78 |
| MA(100) : | 8.12 |
MA(250) : | 11.38 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 8.7 |
D(3) : | 7 |
| RSI | RSI(14): 35.9 |
|||
| 52-week | High : | 19.03 | Low : | 4.19 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CVKD ] has closed above bottom band by 22.3%. Bollinger Bands are 24.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.18 - 5.22 | 5.22 - 5.25 |
| Low: | 4.25 - 4.28 | 4.28 - 4.32 |
| Close: | 5.05 - 5.12 | 5.12 - 5.18 |
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Tue, 31 Mar 2026
Cadrenal Therapeutics (NASDAQ: CVKD) pivots to CAD-1005 and expands clotting disorder pipeline - Stock Titan
Tue, 31 Mar 2026
Cadrenal Therapeutics (NASDAQ: CVKD) widens 2025 loss, advances CAD-1005 toward Phase 3 - Stock Titan
Tue, 31 Mar 2026
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial - GlobeNewswire
Tue, 31 Mar 2026
Drug for rare heparin reaction cut clot events by 25%; FDA maps Phase 3 - Stock Titan
Tue, 16 Dec 2025
Cadrenal Therapeutics Announces New Securities Purchase Agreement - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 22.3 (%) |
| Held by Institutions | 8.6 (%) |
| Shares Short | 75 (K) |
| Shares Short P.Month | 56 (K) |
| EPS | -8.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.33 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -209.3 % |
| Return on Equity (ttm) | -468.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -6.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.59 |
| PEG Ratio | 0 |
| Price to Book value | 3.84 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|